Novo Holdings to acquire Catalent for $11.5 billion; cancer incidence is expected to surge 77% by 2050; Silicon Valley’s county takes a bold step to address the rising loneliness crisis.
Novo Holdings, parent company to Novo Nordisk, is set to acquire Catalent in a significant $11.5 billion deal, signaling a strategic move to expand the production capacity of semaglutide (Wegovy), according to Reuters. Catalent is the main supplier of filling and packaging syringes and injection pens for Novo Nordisk’s weight loss medication. The deal is poised to strengthen Novo Holdings' position in the pharmaceutical industry while addressing the rising global concerns around obesity and related health issues.
The World Health Organization (WHO) has released a concerning report indicating a projected 77% increase in global cancer cases by 2050, according to CNN. The organization has emphasized the urgent need for comprehensive measures to tackle this growing health crisis, advocating for enhanced prevention, early detection, and improved access to treatment. The report underscored the importance of international collaboration and coordinated efforts to implement effective strategies in the battle against cancer, highlighting the pressing need for a unified global response.
San Mateo County in the California Bay Area, which includes part of Silicon Valley, has declared loneliness a public health emergency, acknowledging its profound impact on mental well-being, according to NBC News. This groundbreaking move reflects a growing recognition of the negative health consequences associated with social isolation and underscores the county's commitment to addressing mental health challenges. By designating loneliness as a priority, San Mateo County aims to pioneer innovative solutions and community-based initiatives to foster social connections, setting a precedent for other regions to prioritize mental health in public policy.
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Medication Adherence Star Ratings Measures, Health Care Resource Utilization, and Cost
May 9th 2024For patients prescribed diabetes, hypertension, and hyperlipidemia medications, nonadherence to CMS Star Ratings quality measures of medication adherence was associated with increased health care resource utilization and costs.
Read More